Downloads: 1
India | Pharmacotherapeutics | Volume 11 Issue 6, June 2022 | Pages: 1369 - 1369
Will Dostarlimab Become the New Rectal Cancer Drug of Choice?
Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.
Keywords: Dostarlimab, Rectal cancer, new drug of choice
Rating submitted successfully!
Received Comments
No approved comments available.